Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosus

Table 1 Baseline characteristics of patients in the longitudinal pediatric- and adult-onset systemic lupus erythematosus (pSLE and aSLE) cohorts*

	pSLE	Pediatric controls	aSLE	Adult controls
Sex, ratio, male:female,	10:32	10:12	2:21	16:24
Ethnicity/race, n (%)
Hispanic	21 (50)	5 (23)	2 (9)	6 (15)
Asian	10 (24)	10 (45)	2 (9)	13 (32)
Caucasian	5 (12)	6 (27)	13 (56)	16 (40)
African-American	4 (9)	1 (5)	4 (17)	4 (10)
Other/Mixed	2 (5)	0	2 (9)	1 (3)
Age, years	15.9 ± 3.5	20.2 ± 1.3	42 ± 15	41 ± 10
Age at diagnosis, years	12.7 ± 4.1		32 ± 15
Disease duration, years^†	3.1 ± 3		7.9 ± 8.6
SLEDAI, mean (range)	2.0 (0, 15)		3.0 (0, 12)
SDI, mean (range)	0.9 (0, 5)		0.9 (0, 2)
Glomerulonephritis, n (%)^††	30 (71)		5 (22)
Class II	0		0
Class III	0		0
Class IV	17 (40)		4 (17)
Class V	6 (14)		0
Mixed	5 (12)		0

*Except where indicated otherwise, values are expressed as the mean ± SD and were obtained at the time of study entry. SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; Glomerulonephritis classification as per the International Society of Nephrology/Renal Pathology Society. There was no biopsy done on one aSLE patient with clinical criteria of SLE renal disease. ^†P = 0.002 in pSLE compared with aSLE; ^††P = 0.0005 in pSLE compared with aSLE.

ISSN: 1478-6362